Key Highlights

● ARS Pharmaceuticals shares have fallen sharply, most recently closing at $5.51, down 13.71%, with total Revenue of $33.7 million and a net loss of $62.3 million, or $0.63 per share, in the recent quarter.

● Gross Margin came in around 62%, which management attributed to reserves against short-dated inventory and Manufacturing inefficiencies tied to the international launch.

● An interim data readout for neffy in chronic spontaneous urticaria was pushed from around the end of 2026 to the first quarter of 2027, extending the timeline to a key pipeline catalyst.

● Neffy's U.S. Market Share reached about 5%, roughly double the year-ago level, and the company guided to second-half combined SG&A and R&D of $114 million to $126 million as part of a leaner spending plan.

Shares of ARS Pharmaceuticals (NASDAQ:SPRY) fell sharply in the session following the company's second-quarter 2026 results, landing the neffy maker on lists of the day's biggest decliners. The company reported after the close on 19 August and hosted its Earnings Call on 20 August, and the stock moved lower by roughly 14% around the release. The catalyst is well established: the quarterly print combined a wider-than-expected loss, visible gross-margin pressure, and the disclosure that a closely watched clinical readout has slipped into 2027. Each of those items on its own would have been digestible; together they reset near-term expectations for a company the market has valued as a commercial-stage growth story.

What the quarter actually showed

ARS reported total revenue of $33.7 million for the second quarter, of which net product revenue was $26.2 million, driven primarily by sales of neffy, its needle-free epinephrine nasal spray for severe allergic reactions. The remaining roughly $7.4 million came from Supply agreements tied to ex-U.S. partners. The company posted a net loss of $62.3 million, or $0.63 per share, and ended the quarter with $143.8 million in cash and equivalents as of 30 June 2026.

The commercial metrics management emphasized were directionally positive. neffy's U.S. market share reached about 5%, roughly double the 2.5% level a year earlier, and its share within the targeted prescriber universe rose to about 8% from 4%. The company said it had accumulated roughly 16,000 unique neffy prescribers, a figure it described as having tripled year over year. On the surface, that is the shape of a product still gaining traction in a category long dominated by auto-injectors.

Why the market reacted negatively anyway

The friction sat in profitability and timing. Gross margin came in around 62%, which management attributed to reserves taken against short-dated inventory and to manufacturing inefficiencies, compounded by the cost of launching outside the United States. For a branded specialty product, a margin in the low-60s is well below where investors expect a scaled epinephrine Franchise to operate, and the explanation pointed to execution and inventory issues rather than one-off accounting noise. That raised the question of how quickly margins can normalize as volumes build.

The larger overhang came from the pipeline. ARS has been developing neffy for chronic spontaneous urticaria (CSU) and other indications intended to broaden the product beyond acute anaphylaxis. On the call, management indicated that an interim data readout previously expected around the end of 2026 has been pushed to the first quarter of 2027. Delayed catalysts are a recurring source of de-rating in commercial-stage biotech, because they extend the runway to value-creating milestones and push out the moment when investors can underwrite label expansion. Coming alongside softer margins, the slip amplified concerns that the story's next leg is further away than assumed.

The strategic pivot management is making

Alongside the results, ARS outlined a shift in how it spends to build the neffy brand. The company signaled a move away from broad, expensive direct-to-consumer Marketing toward a more provider-focused commercial model, framing the epinephrine opportunity as a "prevention-based" market that requires changing prescriber behavior rather than driving consumer awareness through mass advertising. Management paired this with a lower spending trajectory: it guided to second-half combined SG&A and R&D of roughly $114 million to $126 million, including $14 million to $16 million of stock-based compensation, and to cash-based operating expenses of about $100 million to $110 million for the second half, which it characterized as roughly a 40% reduction from the first half. The company reiterated a target of reaching cash-flow breakeven by the end of 2027.

For some investors, a leaner cost structure and a defined path to breakeven are constructive. For others, a pivot away from DTC after an expensive launch phase reads as an acknowledgment that the original go-to-market plan was not converting efficiently. The market's immediate reaction suggests the second interpretation carried more weight on the day, particularly with breakeven still more than a year out and dependent on continued share gains.

The financial picture in context

With $143.8 million in cash against a second-quarter net loss of $62.3 million, the runway question is not acute in the immediate term, but it is not comfortable either. The planned reduction in second-half spending is central to management's argument that existing cash can carry the company toward its breakeven goal. That thesis leans heavily on neffy revenue continuing to compound and on gross margin recovering as short-dated inventory reserves and manufacturing inefficiencies work through the system. Any stumble on either front would tighten the math and could reintroduce financing questions.

What investors are weighing now

The distinction between confirmed fact and market interpretation matters here. Confirmed: revenue, the net loss, the cash balance, the margin level, the spending guidance, the breakeven target, and the delay of the CSU interim readout to the first quarter of 2027. Interpretation: whether the margin pressure is transitory or structural, whether the DTC pullback accelerates or slows prescription growth, and whether the pipeline delay signals deeper timeline risk. The sell-off reflects the market pricing in the less charitable reading of each.

What to watch next

The near-term signposts are straightforward. Third-quarter results will show whether market share continues climbing at the pace management described and whether gross margin begins recovering off the second-quarter level. The revised first-quarter 2027 CSU interim readout becomes the key pipeline event, and any further movement in its timing would be significant. Investors will also track quarterly cash burn against the reduced spending guidance to judge how firmly the end-of-2027 breakeven target holds. Until those data points arrive, the debate over whether the drop was an overreaction or a justified reset is unlikely to be settled.